Nektar Therapeutics (NASDAQ:NKTR – Get Rating) Director Roy A. Whitfield sold 30,000 shares of Nektar Therapeutics stock in a transaction dated Wednesday, June 14th. The shares were sold at an average price of $0.57, for a total transaction of $17,100.00. Following the sale, the director now owns 216,250 shares in the company, valued at $123,262.50. […]